2seventy Bio Stock Today

TSVT Stock  USD 2.62  0.13  5.22%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 81

 
High
 
Low
Very High
2Seventy Bio is selling for under 2.62 as of the 31st of January 2025; that is 5.22 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.47. 2Seventy Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 1st of January 2025 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
3rd of November 2021
Category
Healthcare
Classification
Health Care
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2Seventy Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 51.59 M outstanding shares of which 5.08 M shares are at this time shorted by private and institutional investors with about 11.5 trading days to cover. More on 2Seventy Bio

Moving together with 2Seventy Stock

  0.85JNJ Johnson JohnsonPairCorr
  0.62LLY Eli Lilly Earnings Call This WeekPairCorr

Moving against 2Seventy Stock

  0.62MLAB Mesa Laboratories Earnings Call This WeekPairCorr
  0.48BMY Bristol Myers Squibb Earnings Call This WeekPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

2Seventy Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President DirectorNick Leschly
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.290.2
Way Up
Pretty Stable
Gross Profit Margin0.960.8315
Fairly Up
Slightly volatile
Net Debt168.8 M163.5 M
Sufficiently Up
Slightly volatile
Total Current Liabilities66.8 M53.8 M
Fairly Up
Slightly volatile
Non Current Liabilities Total252.6 M287.9 M
Fairly Down
Slightly volatile
Total Assets574.1 M650.2 M
Fairly Down
Slightly volatile
Total Current Assets192.8 M273.4 M
Way Down
Slightly volatile
Debt Levels
2Seventy Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand 2Seventy Bio's financial leverage. It provides some insight into what part of 2Seventy Bio's total assets is financed by creditors.
Liquidity
2Seventy Bio currently holds 256.67 M in liabilities with Debt to Equity (D/E) ratio of 0.73, which is about average as compared to similar companies. 2Seventy Bio has a current ratio of 3.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about 2Seventy Bio's use of debt, we should always consider it together with its cash and equity.

Depreciation

10.31 Million
2Seventy Bio (TSVT) is traded on NASDAQ Exchange in USA. It is located in 60 Binney Street, Cambridge, MA, United States, 02142 and employs 274 people. 2Seventy Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 135.16 M. 2Seventy Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 51.59 M outstanding shares of which 5.08 M shares are at this time shorted by private and institutional investors with about 11.5 trading days to cover. 2Seventy Bio currently holds about 357.93 M in cash with (166.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check 2Seventy Bio Probability Of Bankruptcy
Ownership Allocation
2Seventy Bio holds a total of 51.59 Million outstanding shares. The majority of 2Seventy Bio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 2Seventy Bio to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in 2Seventy Bio. Please pay attention to any change in the institutional holdings of 2Seventy Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check 2Seventy Ownership Details

2Seventy Stock Institutional Holders

InstituionRecorded OnShares
Geode Capital Management, Llc2024-09-30
1.2 M
State Street Corp2024-09-30
1.1 M
Eversept Partners, Llc2024-09-30
998.1 K
Cowen And Company, Llc2024-09-30
800 K
Dafna Capital Management Llc2024-09-30
630 K
Bank Of America Corp2024-09-30
603.1 K
Healthcare Of Ontario Pension Plan Trust Fund2024-09-30
590 K
Venator Management Llc2024-09-30
525 K
Jpmorgan Chase & Co2024-09-30
514.8 K
Kynam Capital Management, Lp2024-09-30
M
Goldman Sachs Group Inc2024-09-30
4.2 M
View 2Seventy Bio Diagnostics

2Seventy Bio Historical Income Statement

At this time, 2Seventy Bio's Net Interest Income is comparatively stable compared to the past year. Depreciation And Amortization is likely to gain to about 10.7 M in 2025, whereas Other Operating Expenses is likely to drop slightly above 226.9 M in 2025. View More Fundamentals

2Seventy Stock Against Markets

2Seventy Bio Corporate Management

Additional Tools for 2Seventy Stock Analysis

When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.